2025 ESC/EAS Dyslipidemia Guidelines Focused Update: Intensifying Prevention, Risk Stratification, and Therapy

The 2025 Focused Update of the European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) Guidelines for the management of lipid disorders marks a significant evolution in cardiovascular disease (CVD) prevention, reflecting contemporary evidence, advances in risk assessment, and the advent of novel therapeutic modalities. Dyslipidemia remains a primary modifiable risk for atherosclerotic cardiovascular disease, necessitating robust, evidence-driven strategies to optimize prevention. Notably, the update transitions from the traditional SCORE system to the more comprehensive SCORE2 and SCORE2-OP risk models for estimating 10-year atherosclerotic cardiovascular disease risk. These new models broaden applicability, encompassing both fatal and non-fatal cardiovascular events and extending risk calculation up to age 89, while recalibrating country-specific risk clusters and prioritizing non-HDL cholesterol over total cholesterol as a core indicator. The guidelines emphasize the intensification of therapy for individuals identified as being at higher risk, integrating recent clinical trial data and targeted drug selection, with a particular focus on individualized risk stratification. This focused update contrasts its recommendations against the 2019 standard, outlining the rationale for new strategies in both primary and secondary prevention through intensified lipid-lowering therapy. Comprehensive implementation of these recommendations is anticipated to drive further reductions in ASCVD events, aligning with global public health priorities. The 2025 guidelines thus serve as an essential tool for clinicians and researchers, supporting nuanced decision-making and reinforcing the central role of lipid management in contemporary cardiovascular risk reduction.